Challenges of Carbapenem-Resistant Enterobacteriaceae in the Development of New β-Lactamase Inhibitors and Antibiotics

Area of Science:

• Microbiology and Infectious Diseases
• Medicinal Chemistry
• Drug Discovery

Background:

• Antimicrobial resistance (AMR), particularly carbapenem-resistant Enterobacteriaceae (CRE), is a critical global health threat.
• CRE infections are difficult to treat due to complex resistance mechanisms involving β-lactamases, reduced permeability, and efflux pumps.
• Current treatment options are limited, and existing inhibitors are not effective against all classes of β-lactamases, especially metallo-β-lactamases (MBLs).

Purpose of the Study:

• To provide a comprehensive overview of current therapeutic strategies against carbapenemase-producing Enterobacteriaceae (CPE).
• To discuss the development of novel carbapenemase inhibitor drug candidates.
• To explore future perspectives in combating AMR.

Main Methods:

• Review of current literature on antimicrobial resistance mechanisms and carbapenemase inhibitors.
• Analysis of the Ambler classification for β-lactamases (SβLs and MβLs).
• Discussion of emerging therapeutic strategies, including chemical optimization, novel drug combinations, and siderophore-antibiotic conjugates.

Main Results:

• Carbapenem resistance involves diverse mechanisms, necessitating a range of inhibitors.
• Novel inhibitors like xeruborbactam show promise with a broader inhibition spectrum, including MBLs.
• Advanced strategies focus on enhancing inhibitor efficacy and bacterial uptake.

Conclusions:

• Developing effective carbapenemase inhibitors is crucial for addressing the global AMR crisis.
• Targeting both serine-β-lactamases (SβLs) and metallo-β-lactamases (MBLs) is essential for broad-spectrum activity.
• Continued research into rational drug design and novel therapeutic approaches is vital for future treatment options.